Clinical Trial Update: Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma [NA]

View source ↗

Summary

This clinical trial update describes a forthcoming study evaluating a combination regimen of Relmacabtagene autoleucel CAR-T cells, autologous hematopoietic ste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Relmacabtagene Autoleucel (relmacabtagene autoleucel)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhengzhou University | Conditions: Primary Central Nervous System Lymphoma (PCNSL) | NA | Status: NOT_YET_RECRUITING